Bioresorbable Vascular Scaffold Market Size, Share, and Growth Forecast, 2026 - 2033

The global bioresorbable vascular scaffold market size is likely to be valued at US$479.2 million in 2026 and is expected to reach US$853.7 million by 2033, growing at a CAGR of 8.6% during the forecast period from 2026 to 2033, driven by the longstanding clinical desire for a "disappearing stent" that provides temporary mechanical vessel support during arterial healing followed by complete bioresorption restoring native vessel vasomotion, enabling non-invasive coronary imaging follow-up without metallic stent artifact, and eliminating the long-term foreign body presence and late adverse events associated with permanent metallic drug-eluting stents.

Driver - Next-generation BVS Technology Innovation Overcoming First-generation Limitations

The development of next-generation bioresorbable vascular scaffold (BVS) platforms is expected to be the primary driver of market recovery and growth during the forecast period. These advanced platforms incorporate thinner strut designs, improved polymer chemistries with more predictable bioresorption, enhanced radiopacity for better fluoroscopic visualization, and optimized drug-coating technologies for controlled antiproliferative drug release, addressing the key limitations associated with Abbott's first-generation Absorb BVS.

Elixir Medical's DESolve NX bioresorbable scaffold, built on a proprietary poly-L-lactic acid (PLLA) polymer platform, features a self-correcting scaffold architecture and 150-micrometer strut thickness. The device has received CE Mark approval and represents a significant advancement in next-generation BVS technology by improving mechanical performance while overcoming the thicker strut limitations of earlier scaffold designs.

Kyoto Medical Plastics' REMEDY bioresorbable coronary scaffold utilizes a novel PDLA/PLLA polymer blend and an ultra-thin 100-micrometer strut architecture comparable to contemporary thin-strut metallic drug-eluting stents. Clinical studies in Japan have demonstrated favorable safety and efficacy outcomes, strengthening confidence in the clinical viability of next-generation BVS platforms and supporting broader market adoption.

Restraint - First-generation Clinical Setback Legacy and Clinical Community Confidence Deficit

The withdrawal of Abbott's Absorb BVS from the market following higher rates of scaffold thrombosis and target vessel failure compared with metallic drug-eluting stents significantly eroded clinician confidence in bioresorbable vascular scaffold (BVS) technology. Restoring confidence remains a key challenge for market growth and will depend on robust clinical evidence demonstrating the safety and efficacy of next-generation BVS platforms.

Rebuilding confidence among interventional cardiologists and hospital decision-makers will require well-designed prospective randomized controlled trials that directly compare next-generation BVS platforms with contemporary thin-strut metallic drug-eluting stents, the current standard of care. Such evidence is expected to be more influential in driving clinical adoption than observational registry studies, which are generally considered less rigorous by the cardiovascular device community.

Opportunity - Magnesium-based Bioresorbable Metallic Scaffold Platforms and Next-generation Polymer Technology

The development of bioresorbable metallic scaffold platforms is opening new growth opportunities in coronary intervention. Unlike conventional polymer-based bioresorbable vascular scaffolds (BVS), Biotronik's DREAMS (Drug-Eluting Absorbable Metal Scaffold) utilizes a magnesium alloy, representing a distinct technological approach to temporary vascular scaffolding. Magnesium-based scaffolds provide adequate mechanical support during the critical vessel healing period while gradually resorbing over time.

The magnesium alloy is absorbed through well-established metabolic pathways, offering more predictable resorption kinetics than polymer-based BVS platforms. This controlled degradation process may also promote a more consistent vascular healing response, reinforcing clinical interest in next-generation bioresorbable scaffold technologies.

Application Insights

Coronary artery application is expected to dominate the market, commanding around 62% of global revenue in 2026. The coronary artery segment holds the largest share of the bioresorbable vascular scaffold (BVS) market. Its leadership reflects the early development of BVS technology for coronary interventions. Abbott's Absorb platform pioneered the use of BVS in coronary artery disease treatment. This technology has generated extensive clinical evidence and regulatory experience. It has also increased awareness and adoption among interventional cardiologists. Abbott Laboratories pioneered coronary BVS adoption with its Absorb BVS platform, which was extensively evaluated in major ABSORB clinical trials, making coronary PCI the leading application area for bioresorbable scaffold technology.

Peripheral artery application represents the fastest-growing segment, driven by the particularly strong clinical rationale for bioresorbable scaffolding in peripheral vascular disease, where metallic stent limitations, including fracture risk in flexion-exposed arterial segments, imaging artifact on CT/MRI follow-up, and poor long-term outcomes in small-caliber below-knee vessels create compelling unmet clinical need for bioresorbable scaffold alternatives.

End-user Insights

Hospitals are estimated to dominate the market, accounting for around 70% of global revenue in 2026, owing to their advanced catheterization laboratories, intravascular imaging capabilities (IVUS/OCT), experienced interventional specialists, and comprehensive post-procedural care infrastructure required for BVS implantation. Mayo Clinic utilizes advanced catheterization labs, IVUS/OCT imaging, and specialized interventional cardiology teams, highlighting why hospitals dominate the BVS implantation market.

Ambulatory care centers (ASCs) are likely to be the fastest-growing end-user segment, driven by the increasing shift of lower-complexity PCI and cardiac catheterization procedures to outpatient settings, supported by favorable reimbursement policies and rising demand for elective coronary interventions outside hospitals. Cardiovascular Institute of the South (CIS) has expanded outpatient cardiac catheterization and PCI services through its ambulatory facilities, reflecting the growing trend of performing lower-risk coronary interventions in ASC and outpatient settings.

North America Bioresorbable Vascular Scaffold Market Trends

North America is projected to account for 38% of the global bioresorbable vascular scaffold market revenue in 2026, making it the largest regional market. The region's leadership is supported by the high volume of coronary and peripheral vascular interventions in the U.S., a well-established cardiovascular device innovation ecosystem led by companies such as Abbott and Elixir Medical, and increasing investment in the clinical development of next-generation BVS technologies.

U.S. Bioresorbable Vascular Scaffold Market Insights

The U.S. is projected to remain the largest market, accounting for about 80% of the North America bioresorbable vascular scaffold market in 2026. Its leading position is supported by an extensive network of cardiac catheterization laboratories, a large patient population with coronary and peripheral vascular diseases requiring interventional treatment, and a robust clinical research ecosystem focused on the development and evaluation of next-generation BVS technologies.

Canada Bioresorbable Vascular Scaffold Market Insights

Canada is expected to account for nearly 20% of the North American bioresorbable vascular scaffold market in 2026. Market growth is supported by the country's well-established interventional cardiology and vascular intervention capabilities at leading academic medical centers, Health Canada's regulatory framework for the approval of novel coronary devices, and the active participation of Canadian cardiovascular centers in international clinical trials evaluating next-generation BVS technologies.

Europe Bioresorbable Vascular Scaffold Market Trends

Europe is projected to be the second-largest regional market, accounting for over 28% of global bioresorbable vascular scaffold revenue in 2026. The region's strong market position is supported by the earlier clinical adoption of CE Mark-approved BVS technologies compared with the more stringent U.S. FDA premarket approval pathway, the presence of leading BVS developers such as Biotronik and B. Braun Melsungen AG, and the European interventional cardiology community's active participation in bioresorbable scaffold research through European Society of Cardiology initiatives, clinical trials, and registry programs.

Germany Bioresorbable Vascular Scaffold Market Trends

Germany is projected to lead the European bioresorbable vascular scaffold market, accounting for approximately 30% of the regional market in 2026. Its leadership is driven by the presence of leading BVS developers, including Biotronik AG and B. Braun Melsungen AG. Germany's position is further strengthened by Biotronik's DREAMS magnesium-based bioresorbable scaffold program, which offers a differentiated alternative to polymer-based BVS technologies through its innovative bioresorbable metallic scaffold design.

U.K. Bioresorbable Vascular Scaffold Market Trends

The U.K. is anticipated to account for about15% of the European bioresorbable vascular scaffold market in 2026. Market growth is supported by NICE technology appraisal processes that guide the clinical adoption of cardiovascular devices, NHS procurement frameworks governing cardiac device purchasing, and the British Cardiovascular Intervention Society's (BCIS) ongoing evaluation of emerging clinical evidence to inform interventional cardiology practice recommendations.

Asia Pacific Bioresorbable Vascular Scaffold Market Trends

Asia Pacific is projected to be the fastest-growing regional market for bioresorbable vascular scaffolds during the forecast period. Growth is driven by the region's large and increasing cardiovascular disease burden, rapid expansion of interventional cardiology and vascular intervention infrastructure, Japan's leadership in bioresorbable scaffold clinical research, and China's expanding cardiovascular device market, which is fostering the development of next-generation domestic BVS platforms.

Japan Bioresorbable Vascular Scaffold Market Trends

Japan is projected to command 45% of the total share in 2026, reflecting the country's pioneering clinical research contributions to BVS science through Japanese interventional cardiology academic centers, the Japanese Cardiovascular Society's active engagement with BVS clinical evidence evaluation, and Kyoto Medical Plastics' development of the REMEDY next-generation bioresorbable coronary scaffold platform with ultra-thin strut architecture.

India Bioresorbable Vascular Scaffold Market Trends

India is expected to account for approximately 40% of the Asia Pacific bioresorbable vascular scaffold market in 2026, although the market remains at an early stage of development. Current adoption is concentrated in leading private tertiary care hospitals, including Apollo Hospitals, Narayana Health, and Fortis Healthcare, which have well-established interventional cardiology programs and access to advanced cardiovascular technologies through global medical device partnerships.

The global bioresorbable vascular scaffold market is characterized by a competitive landscape focused on technological advancement following the commercial withdrawal of first-generation BVS platforms. Established cardiovascular device manufacturers, specialized BVS developers, and vascular device companies are investing in a diverse pipeline of next-generation technologies, including polymer-based coronary scaffolds, magnesium-based bioresorbable metallic scaffolds, and peripheral vascular BVS platforms.

Abbott continues to invest in next-generation coronary BVS development, leveraging clinical and technical insights gained from the Absorb BVS program to develop an improved scaffold platform capable of addressing the limitations of first-generation devices and competing in the global coronary stent market. Meanwhile, Elixir Medical's DESolve NX, which has received CE Mark approval, is among the most advanced next-generation polymer-based BVS platforms in development. Its ongoing DESSERT clinical trial program is expected to generate additional evidence supporting the safety and efficacy of next-generation bioresorbable scaffold technology.

Key Industry Developments:

• In September 2023, Zeus expanded its bioabsorbable product portfolio by launching Absorv™ XSE oriented tubing, a customizable advanced polymer platform available in multiple resin options and expanded size ranges. The company designed the product to provide medical device manufacturers with a bioabsorbable alternative to permanently implanted metallic devices, supporting the development of next-generation implantable technologies.